U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

Cover of Rivaroxaban (Xarelto)

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet].

Show details

APPENDIX 6DEFINITIONS OF PRIMARY OUTCOMES USED IN THE EINSTEIN TRIALS

The following definitions were applied by the central independent adjudication committee to confirm a suspected episode of symptomatic recurrent DVT or PE:

  1. Suspected (recurrent) DVT with one of the following findings:
    1. abnormal compression ultrasound (CUS) where compression had been normal or, if non-compressible during screening, a substantial increase (4 mm or more) in diameter of the thrombus during full compression
    2. an extension of an intraluminal filling defect, or a new intraluminal filling defect or an extension of non-visualization of veins in the presence of a sudden cut-off on venography.
      or
  2. Suspected PE with one of the following findings:
    1. a (new) intraluminal filling defect in segmental or more proximal branches on spiral computed tomography scan
    2. a (new) intraluminal filling defect or an extension of an existing defect or a new sudden cut-off of vessels more than 2.5 mm in diameter on the pulmonary angiogram
    3. a (new) perfusion defect of at least 75% of a segment with a local normal ventilation result (high probability) on ventilation/perfusion lung scintigraphy
    4. inconclusive spiral computed tomography, pulmonary angiography, or lung scintigraphy with demonstration of DVT in the lower extremities by CUS or venography.
  3. Fatal PE was:
    1. PE based on objective diagnostic testing, autopsy
    2. death which cannot be attributed to a documented cause and for which DVT/PE cannot be ruled out (unexplained death).

Without objective testing (see Section 3), a suspected episode of DVT or PE was to be considered as confirmed if it led to a change in anticoagulant treatment at therapeutic dosages for more than 48 hours.

Copyright © CADTH 2015.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK344312

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...